TIMPs as multifacial proteins

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 3, 2004, Pages 187-198

  Lambert, Elise ^a   Dassé, Emilie ^a   Haye, Bernard ^a   Petitfrère, Emmanuelle ^a  

^a Moulin de la Housse   (France)

Author keywords

Biological activities; Cancer; Hematopoiesis; Matrix metalloproteinases (MMPs); Tissue inhibitors of metalloproteinases (TIMPs)

Indexed keywords

BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ANGIOGENESIS; APOPTOSIS; BODY FLUID; CANCER; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL; ERYTHROLEUKEMIA CELL; EXTRACELLULAR MATRIX; HEMATOPOIESIS; HUMAN; METASTASIS; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STEROIDOGENESIS; TISSUE; TISSUE REGENERATION; WOUND HEALING;

EID: 1342279517     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2003.09.008     Document Type: Review

References (121)

1. Woessner Jr JF, Matrix metalloproteinases and their inhibitors in connective tissue remodeling, Faseb J 1991:52145-54.
2. Werb Z., Ashkenas J., MacAuley A., Wiesen J.F. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development. Braz. J. Med. Biol. Res. 29:1996;1087-1097.
3. Woessner Jr JF, Nagase H. Matrix metalloproteinases and TIMPs. London: Oxford University Press, Biological roles of the MMPs. 2000, pp. 126-38.
4. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 74:1997;111-122.
5. Greene J., Wang M., Liu Y.E.et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 271:1996;30375-30380.
6. Leco K.J., Apte S.S., Taniguchi G.T.et al. Murine tissue inhibitor of metalloproteinases-4 (Timp-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett. 401:1997;213-217.
7. Wilhelm S.M., Collier I.E., Marmer B.L.et al. SV40-transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J. Biol. Chem. 264:1989;17213-17221.
8. Ward R.V., Hembry R.M., Reynolds J.J., Murphy G. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. Biochem. J. 278:1991;179-187.
9. Howard E.W., Banda M.J. Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J. Biol. Chem. 266:1991;17972-17977.
10. Butler G.S., Apte S.S., Willenbrock F., Murphy G. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B, regulation by polyanions. J. Biol. Chem. 274:1999;10846-10851.
11. Bigg H.F., Shi Y.E., Liu Y.E., Steffensen B., Overall C.M. Specific, high affinity binding of tissue inhibitor of metalloproteinases-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. TIMP-4 binds progelatinase A and the COOH-terminal domain in a similar manner to TIMP-2. J. Biol. Chem. 272:1997;15496-15500.
12. Bode W., Maskos K. Structural studies on MMPs and TIMPs. Methods Mol. Biol. 151:2001;45-77.
13. Kashiwagi M., Tortorella M., Nagase H., Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J. Biol. Chem. 276:2001;12501-12504.
14. Amour A., Slocombe P.M., Webster A.et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 473:2000;275-279.
15. Williamson R.A., Carr M.D., Frenkiel T.A., Feeney J., Freedman R.B. Mapping the binding site for matrix metalloproteinase on the N-terminal domain of the tissue inhibitor of metalloproteinases-2 by NMR chemical shift perturbation. Biochemistry. 36:1997;13882-13889.
16. Tuuttila A., Morgunova E., Bergmann U.et al. Three-dimensional structure of human tissue inhibitor of metalloproteinases-2 at 2.1 A resolution. J. Mol. Biol. 284:1998;1133-1140.
17. Caterina N.C., Windsor L.J., Yermovsky A.E.et al. Replacement of conserved cysteines in human tissue inhibitor of metalloproteinases-1. J. Biol. Chem. 272:1997;32141-32149.
18. Caterina N.C., Windsor L.J., Bodden M.K.et al. Glycosylation and N-terminal domain mutants of the tissue inhibitor of metalloproteinases-1 (TIMP-1). Biochim. Biophys. Acta. 1388:1998;21-34.
19. Welgus H.G., Campbell E.J., Bar-Shavit Z., Senior R.M., Teitelbaum S.L. Human alveolar macrophages produce a fibroblast-like collagenase and collagenase inhibitor. J. Clin. Invest. 76:1985;219-224.
20. Bord S., Horner A., Beeton C.A., Hembry R.M., Compston J.E. Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) distribution in normal and pathological human bone. Bone. 24:1999;229-235.
21. Cawston T.E., Noble D.N., Murphy G.et al. Rapid purification of tissue inhibitor of metalloproteinases from human plasma and identification as a gamma-serum protein. Biochem. J. 238:1986;677-682.
22. Murate T., Yamashita K., Isogai C.et al. The production of tissue inhibitors of metalloproteinases (TIMPs) in megakaryopoiesis: possible role of platelet- and megakaryocyte-derived TIMPs in bone marrow fibrosis. Br. J. Haematol. 99:1997;181-189.
23. Ries C., Loher F., Zang C., Ismair M.G., Petrides P.E. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes. Clin. Cancer Res. 5:1999;1115-1124.
24. Kadri Z., Petitfrere E., Boudot C.et al. Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. Cell. Growth Differ. 11:2000;573-580.
25. Sato T., Koike L., Miyata Y.et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res. 62:2002;1025-1029.
26. Sohara N., Trojanowska M., Reuben A., Oncostatin M. stimulates tissue inhibitor of metalloproteinase-1 via a MEK-sensitive mechanism in human myofibroblasts. J. Hepatol. 36:2002;191-199.
27. Overall C.M. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann. N. Y. Acad. Sci. 732:1994;51-64.
28. Clark S.D., Kobayashi D.K., Welgus H.G. Regulation of the expression of tissue inhibitor of metalloproteinases and collagenase by retinoids and glucocorticoids in human fibroblasts. J. Clin. Invest. 80:1987;1280-1288.
29. Murate T., Yamashita K., Ohashi H.et al. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity. Exp. Hematol. 21:1993;169-176.
30. Hayakawa T., Yamashita K., Tanzawa K., Uchijima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 298:1992;29-32.
31. Westbrook C.A., Gasson J.C., Gerber S.E., Selsted M.E., Golde D.W. Purification and characterization of human T-lymphocyte-derived erythroid-potentiating activity. J. Biol. Chem. 259:1984;9992-9996.
32. Bertaux B., Hornebeck W., Eisen A.Z., Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J. Invest. Dermatol. 97:1991;679-685.
33. Fata J.E., Leco K.J., Moorehead R.A., Martin D.C., Khokha R. Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev. Biol. 211:1999;238-254.
34. Wang T., Yamashita K., Iwata K., Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP-1) and TIMP-2 activate Ras but through different pathways. Biochem. Biophys. Res. Commun. 296:2002;201-205.
35. Kikuchi K., Kadono T., Furue M., Tamaki K. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J. Invest. Dermatol. 108:1997;281-284.
36. Zhao W.Q., Li H., Yamashita K.et al. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) in the nuclei of human gingival fibroblasts. J. Cell. Sci. 111(Pt 9):1998;1147-1153.
37. Yamashita K., Suzuki M., Iwata H.et al. Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett. 396:1996;103-107.
38. Saika S., Kawashima Y., Okada Y.et al. Recombinant TIMP-1 and -2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelium in situ. Curr. Eye. Res. 17:1998;47-52.
39. Corcoran M.L., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J. Biol. Chem. 270:1995;13453-13459.
40. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell. Sci. 107:1994;2373-2379.
41. Guedez L., Stetler-Stevenson W.G., Wolff L.et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J. Clin. Invest. 102:1998;2002-2010.
42. Chesler L., Golde D.W., Bersch N., Johnson M.D. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood. 86:1995;4506-4515.
43. Wingfield P.T., Sax J.K., Stahl S.J.et al. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J. Biol. Chem. 274:1999;21362-21368.
44. Emmert-Buck M.R., Emonard H.P., Corcoran M.L.et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett. 364:1995;28-32.
45. Guedez L., McMarlin A.J., Kingma D.W.et al. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am. J. Pathol. 158:2001;1207-1215.
46. Murphy A.N., Unsworth E.J., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J. Cell. Physiol. 157:1993;351-358.
47. Miyake H., Hara I., Gohji K.et al. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin. Cancer Res. 5:1999;2824-2829.
48. Bello L., Lucini V., Carrabba G.et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation, and invasion by a naturally occurring fragment of human metalloproteinase-2. Cancer Res. 61:2001;8730-8736.
49. Yang T.T., Hawkes S.P. Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci U.S.A. 89:1992;10676-10680.
50. Celiker M.Y., Wang M., Atsidaftos E.et al. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DN.A. Oncogene. 20:2001;4337-4343.
51. Li G., Fridman R., Kim H.R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res. 59:1999;6267-6275.
52. Stetler-Stevenson M., Mansoor A., Lim M.et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood. 89:1997;1708-1715.
53. Valente P., Fassina G., Melchiori A.et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer. 75:1998;246-253.
54. Matsumoto H., Ishibashi Y., Ohtaki T.et al. Newly established murine pituitary folliculo-stellate-like cell line (TtT/GF) secretes potent pituitary glandular cell survival factors, one of which corresponds to metalloproteinase inhibitor. Biochem. Biophys. Res. Commun. 194:1993;909-915.
55. Baker A.H., Zaltsman A.B., George S.J., Newby A.C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. 101:1998;1478-1487.
56. Murphy F.R., Issa R., Zhou X.et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J. Biol. Chem. 277:2002;11069-11076.
57. Boujrad N., Ogwuegbu S.O., Garnier M.et al. Identification of a stimulator of steroid hormone synthesis isolated from testis. Science. 268:1995;1609-1612.
58. Nothnick W.B., Curry T.E. Divergent effects of interleukin-1 beta on steroidogenesis and matrix metalloproteinase inhibitor expression and activity in cultured rat granulosa cells. Endocrinology. 137:1996;3784-3790.
59. Duncan W.C., Illingworth P.J., Fraser H.M. Expression of tissue inhibitor of metalloproteinases-1 in the primate ovary during induced luteal regression. J. Endocrinol. 151:1996;203-213.
60. Nothnick W.B., Soloway P.D., Curry T.E. Pattern of messenger ribonucleic acid expression of tissue inhibitors of metalloproteinases (TIMPs) during testicular maturation in male mice lacking a functional TIMP-1 gene. Biol. Reprod. 59:1998;364-370.
61. Risau W. Mechanisms of angiogenesis. Nature. 386:1997;671-674.
62. Folkman J. Transplacental carcinogenesis by stilbestrol. N. Engl. J. Med. 285:1971;404-405.
63. Takigawa M., Nishida Y., Suzuki F.et al. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP and TIMP-2). Biochem. Biophys. Res. Commun. 171:1990;1264-1271.
64. Bloomston M., Shafii A., Zervos E.E., Rosemurgy A.S. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J. Surg. Res. 102:2002;39-44.
65. Johnson M.D., Kim H.R., Chesler L.et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell Physiol. 160:1994;194-202.
66. Lee S., Zheng M., Kim B., Rouse B.T. Role of matrix metalloproteinase-9 in angiogenesis caused by ocular infection with herpes simplex virus. J. Clin. Invest. 110:2002;1105-1111.
67. Taraboletti G., Garofalo A., Belotti D.et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87:1995;293-298.
68. Ala-Aho R., Johansson N., Baker A.H., Kahari V.M. Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int. J. Cancer. 97:2002;283-289.
69. Kang J.A., Kim J.T., Song H.S.et al. Anti-angiogenic and anti-tumor invasive activities of tissue inhibitor of metalloproteinase-3 from shark, Scyliorhinus torazame. Biochim. Biophys. Acta. 1620:2003;59-64.
70. Behrendtsen O., Werb Z. Metalloproteinases regulate parietal endoderm differentiating and migrating in cultured mouse embryos. Dev. Dyn. 208:1997;255-265.
71. Brenner C.A., Adler R.R., Rappolee D.A., Pedersen R.A., Werb Z. Genes for extracellular-matrix-degrading metalloproteinases and their inhibitor, TIMP, are expressed during early mammalian development. Genes. Dev. 3:1989;848-859.
72. Alexander C.M., Hansell E.J., Behrendtsen O.et al. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. Development. 122:1996;1723-1736.
73. Smith M.F., Ricke W.A., Bakke L.J., Dow M.P., Smith G.W. Ovarian tissue remodeling: role of matrix metalloproteinases and their inhibitors. Mol. Cell Endocrinol. 191:2002;45-56.
74. Hicks N.J., Ward R.V., Reynolds J.J. A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumour cell lines. Int. J. Cancer. 33:1984;835-844.
75. Liotta L.A., Stetler-Stevenson W.G., Steeg P.S. Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest. 9:1991;543-551.
76. Tanaka K., Iwamoto Y., Ito Y.et al. Cyclic AMP-regulated synthesis of the tissue inhibitors of metalloproteinases suppresses the invasive potential of the human fibrosarcoma cell line HT1080. Cancer Res. 55:1995;2927-2935.
77. Yoshiji H., Gomez D.E., Thorgeirsson U.P. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int. J. Cancer. 69:1996;131-134.
78. Ree A.H., Florenes V.A., Berg J.P.et al. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 3:1997;1623-1628.
79. Li L., Zhang S., Lin H., Lin J.Y. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas. Ai Zheng. 21:2002;305-310.
80. Korem S., Kraiem Z., Shiloni E.et al. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr. Med. Assoc. J. 4:2002;247-251.
81. Visscher D.W., Hoyhtya M., Ottosen S.K.et al. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int. J. Cancer. 59:1994;339-344.
82. Airola K., Karonen T., Vaalamo M.et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br. J. Cancer. 80:1999;733-743.
83. Henriet P., Blavier L., Declerck Y.A. Tissue inhibitors of metalloproteinases (TIMP) in invasion and proliferation. Apmis. 107:1999;111-119.
84. DeClerck Y.A., Perez N., Shimada H.et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 52:1992;701-708.
85. Albini A., Melchiori A., Santi L.et al. Tumor cell invasion inhibited by TIMP-2. J. Natl. Cancer Inst. 83:1991;775-779.
86. Khokha R., Waterhouse P., Yagel S.et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science. 243:1989;947-950.
87. Michael M., Babic B., Khokha R.et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J. Clin. Oncol. 17:1999;1802-1808.
88. Yu A.E., Hewitt R.E., Connor E.W., Stetler-Stevenson W.G. Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging. 11:1997;229-244.
89. Jones L., Ghaneh P., Humphreys M., Neoptolemos J.P. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann. N. Y. Acad. Sci. 880:1999;288-307.
90. Baker E.A., Bergin F.G., Leaper D.J. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging. Br. J. Surg. 87:2000;1215-1221.
91. Zucker S., Cao J., Chen W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 19:2000;6642-6650.
92. Wang X., Fu X., Brown P.D., Crimmin M.J., Hoffman R.M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54:1994;4726-4728.
93. Davies B., Brown P.D., East N., Crimmin M.J., Balkwill F.R. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53:1993;2087-2091.
94. Evans J.D., Stark A., Johnson C.D.et al. A phase II trial of marimastat in advanced pancreatic cancer. Br. J. Cancer. 85:2001;1865-1870.
95. Bramhall S.R., Hallissey M.T., Whiting J.et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer. 86:2002;1864-1870.
96. Bian J., Wang Y., Smith M.R.et al. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis. 17:1996;1805-1811.
97. Park M.J., Park I.C., Hur J.H.et al. Modulation of phorbol ester-induced regulation of matrix metalloproteinases and tissue inhibitors of metalloproteinases by SB203580, a specific inhibitor of p38 mitogen-activated protein kinase. J. Neurosurg. 97:2002;112-118.
98. Nagase H., Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res. 4(Suppl 3):2002;S51-S61.
99. Cluitmans F.H., Esendam B.H., Veenhof W.F.et al. The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis. Ann. Hematol. 75:1997;27-31.
100. Obinata M., Yanai N. Cellular and molecular regulation of an erythropoietic inductive microenvironment (EIM). Cell. Struct. Funct. 24:1999;171-179.
101. Janowska-Wieczorek A., Marquez L.A., Matsuzaki A.et al. Expression of matrix metalloproteinases (MMP-2 and -9) and tissue inhibitors of metalloproteinases (TIMP-1 and -2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 105:1999;402-411.
102. Janowska-Wieczorek A., Marquez L.A., Dobrowsky A., Ratajczak M.Z., Cabuhat M.L. Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines. Exp. Hematol. 28:2000;1274-1285.
103. Edwards D.R., Rocheleau H., Sharma R.R.et al. Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. Biochim. Biophys. Acta. 1171:1992;41-55.
104. Gauwerky C.E., Lusis A.J., Golde D.W. Erythroid-potentiating activity: characterization and target cells. Exp. Hematol. 8(Suppl 8):1980;117-127.
105. Hayakawa T., Yamashita K., Kishi J., Harigaya K. Tissue inhibitor of metalloproteinases from human bone marrow stromal cell line KM 102 has erythroid-potentiating activity, suggesting its possibly bifunctional role in the hematopoietic microenvironment. FEBS Lett. 268:1990;125-128.
106. Avalos B.R., Kaufman S.E., Tomonaga M.et al. K562 cells produce and respond to human erythroid-potentiating activity. Blood. 71:1988;1720-1725.
107. Docherty A.J., Lyons A., Smith B.J.et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 318:1985;66-69.
108. Gasson J.C., Golde D.W., Kaufman S.E.et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature. 315:1985;768-771.
109. Stetler-Stevenson W.G., Bersch N., Golde D.W. Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. 296:1992;231-234.
110. Petitfrere E., Kadri Z., Boudot C.et al. Involvement of the p38 mitogen-activated protein kinase pathway in tissue inhibitor of metalloproteinases-1-induced erythroid differentiation. FEBS Lett. 485:2000;117-121.
111. Lambert E., Boudot C., Kadri Z.et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem. J. 37:2003;767-774.
112. Luparello C., Avanzato G., Carella C., Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res. Treat. 54:1999;235-244.
113. Sobue T., Hakeda Y., Kobayashi Y.et al. Tissue inhibitor of metalloproteinases 1 and 2 directly stimulate the bone-resorbing activity of isolated mature osteoclasts. J. Bone Miner Res. 16:2001;2205-2214.
114. Kraling B.M., Wiederschain D.G., Boehm T.et al. The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro. J. Cell Sci. 112:1999;1599-1609.
115. Hoegy S.E., Oh H.R., Corcoran M.L., Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J. Biol. Chem. 276:2001;3203-3214.
116. Edwards D.R., Beaudry P.P., Laing T.D.et al. The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. Int J Obes Relat Metab Disord. 20(Suppl 3):1996;S9-S15.
117. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell. Biol. 74:1997;111-122.
118. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115:2002;3719-3727.
119. Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (TIMPs): a new aspect involving osteoclastic bone resorption. J. Bone Miner Metab. 20:2002;1-13.
120. Douglas D.A., Shi Y.E., Sang Q.A. Computational sequence analysis of the tissue inhibitor of metalloproteinase family. J. Protein Chem. 16:1997;237-255.
121. Gomis-Ruth F.X., Maskos K., Betz M.et al. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature. 389:1997;77-81.